NHS England is launching a new initiative to help smokers quit by offering a varenicline pill a.k.a Stop Smoking Pill, a once-a-day pill that is as effective as vapes in aiding cessation. Annually, 85,000 smokers will receive this medication, aiming to save 9,500 lives over the next five years. The drug, previously marketed as Champix, was reapproved after addressing impurities.
NHS England is introducing a new initiative to help smokers quit by offering a pill that experts claim significantly boosts the chances of quitting. The drug, varenicline, will be made available to hundreds of thousands of smokers across England, with the goal of saving thousands of lives by reducing smoking-related health risks.
Table of Contents
NHS England Plans to Offer Varenicline to 85,000 Smokers Annually
Starting soon, NHS England plans to offer varenicline to around 85,000 smokers annually, giving them a valuable tool in their efforts to quit. Varenicline, a once-a-day tablet, has been proven to be as effective as vapes in aiding people to stop smoking, offering a safe and clinically approved option for smokers trying to break the habit.
Amanda Pritchard, the CEO of NHS England, called the pill a “gamechanger” in the ongoing battle against smoking. The medication works by reducing cravings for nicotine and preventing nicotine from affecting the brain in the usual way, which is often one of the biggest challenges in quitting smoking. Varenicline has also been found to alleviate withdrawal symptoms like irritability and trouble sleeping.
The Drug’s Benefits and Its Role in NHS England’s Smoking Reduction Goals
NHS England aims to continue its progress in reducing the smoking population, which has decreased by over 20% in the last two decades. Currently, only 11.6% of adults in England smoke, which equates to around 6 million people. NHS officials hope that introducing varenicline will prevent 9,500 smoking-related deaths over the next five years, significantly impacting public health outcomes.
The pill was originally sold under the brand name Champix starting in 2006 and was widely used until it was temporarily pulled from the market in July 2021 due to impurities found by the Medicines and Healthcare products Regulatory Agency (MHRA). However, these issues have since been resolved, and the MHRA has approved a new generic version of the drug. NHS England will now provide this affordable version, sourced from pharmaceutical company Teva UK.
Cost-Effectiveness and Research-Backed Success
A study by University College London supports the affordability of varenicline, showing that for every £1 spent on the drug, the NHS will save £1.65 in healthcare costs. This makes the medication not only an effective treatment for smokers but also a cost-effective option for the public healthcare system.
Expert Support for Varenicline’s i.e. Stop Smoking Pill’s Return
Many smoking experts have welcomed the return of varenicline. Dr. Nicola Lindson, an associate professor at Oxford University, stated that varenicline is “one of the most effective ways to quit smoking, especially when combined with behavioural support like counselling.” Hazel Cheeseman, CEO of Action on Smoking and Health, also praised the move but emphasized that the NHS should provide additional support for smokers, such as guidance and counseling, to increase the chances of success.
Broader Challenges for NHS England
Despite the promising outlook for varenicline, NHS England faces ongoing challenges. Hospital leaders recently expressed concerns about the Labour party’s goal to reduce NHS waiting times by mid-2029, stating that it is unlikely to be achieved due to ongoing staffing and resource shortages. With a backlog of patients and fewer resources than needed, NHS trust leaders are concerned about the system’s ability to meet targets.
Additionally, as winter approaches, NHS leaders are concerned about how the service will cope with the expected seasonal pressures. Saffron Cordery, deputy CEO of NHS Providers, remarked that while progress will be made on waiting times, meeting the 18-week target is “difficult and challenging to predict.”
A Step Forward in Smoking Cessation
NHS England’s introduction of varenicline represents a significant step in reducing smoking rates and improving public health. With its proven effectiveness and cost-saving benefits, this initiative has the potential to make a substantial impact in the fight against smoking and the prevention of related diseases. However, it is crucial that the NHS continues to focus on providing comprehensive support to help smokers quit for good.
